Targeting the MAGE A3 antigen in pancreatic cancer

Surgery (United States)

Volumn 152, Issue 3 SUPPL., 2012, Pages

  Cogdill, Alexandria P ^a   Frederick, Dennie T ^a   Cooper, Zachary A ^a   Garber, Haven R ^a   Ferrone, Cristina R ^a   Fiedler, Amy ^a   Rosenberg, Laura ^a   Thayer, Sarah P ^a   Warshaw, Andrew L ^a   Wargo, Jennifer A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GEMCITABINE; MELANOMA ANTIGEN 3; TRICHOSTATIN A; VALPROIC ACID;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYTOKINES; DEOXYCYTIDINE; DNA METHYLATION; HUMANS; HYDROXAMIC ACIDS; IMMUNOTHERAPY; MALE; NEOPLASM PROTEINS; PANCREAS; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TESTIS; VALPROIC ACID;

EID: 84865245406     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.05.031     Document Type: Article

References (26)

1. A.L. Warshaw, and C. Fernandez-del Castillo Pancreatic carcinoma N Engl J Med 326 1992 455 465
2. M.E. Dudley, J.R. Wunderlich, J.C. Yang, R.M. Sherry, S.L. Topalian, and N.P. Restifo Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2005 2346 2357
3. R.A. Morgan, M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, and R.M. Sherry Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126 129
4. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
5. W. Sienel, C. Varwerk, A. Linder, D. Kaiser, M. Teschner, and M. Delire Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study Eur J Cardiothorac Surg 25 2004 131 134
6. V.G. Brichard, and D. Lejeune GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development Vaccine 25 Suppl 2 2007 B61 B71
7. N. Peled, A.B. Oton, F.R. Hirsch, and P. Bunn MAGE A3 antigen-specific cancer immunotherapeutic Immunotherapy 1 2009 19 25
8. N. Chinnasamy, J.A. Wargo, Z. Yu, M. Rao, T.L. Frankel, and J.P. Riley A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer J Immunol 186 2011 685 696
9. E.M. Jaffee, R.H. Hruban, B. Biedrzycki, D. Laheru, K. Schepers, and P.R. Sauter Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 19 2001 145 156
10. P. Brossart, K.S. Heinrich, G. Stuhler, L. Behnke, V.L. Reichardt, and S. Stevanovic Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies Blood 93 1999 4309 4317
11. F.H. Schmitz-Winnenthal, L.V. Galindo-Escobedo, D. Rimoldi, W. Geng, P. Romero, and M. Koch Potential target antigens for immunotherapy in human pancreatic cancer Cancer Lett 252 2007 290 298
12. J. Kim, H.A. Reber, O.J. Hines, K.K. Kazanjian, A. Tran, and X. Ye The clinical significance of MAGEA3 expression in pancreatic cancer Int J Cancer 118 2006 2269 2275
13. F. Brasseur, D. Rimoldi, D. Lienard, B. Lethe, S. Carrel, and F. Arienti Expression of MAGE genes in primary and metastatic cutaneous melanoma Int J Cancer 63 1995 375 380
14. M.J. Scanlan, A.J. Simpson, and L.J. Old The cancer/testis genes: review, standardization, and commentary Cancer Immun 4 2004 1
15. M. Otte, M. Zafrakas, L. Riethdorf, U. Pichlmeier, T. Loning, and F. Janicke MAGE-A gene expression pattern in primary breast cancer Cancer Res 61 2001 6682 6687
16. K. Tsuneyama, M. Sasaki, T. Shimonishi, and Y. Nakanuma Expression of MAGE-A3 in intrahepatic cholangiocarcinoma and its precursor lesions Pathol Int 54 2004 181 186
17. M.J. Scanlan, A.O. Gure, A.A. Jungbluth, L.J. Old, and Y.T. Chen Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunol Rev 188 2002 22 32
18. T. Bert, N. Lubomierski, S. Gangsauge, K. Munch, H. Printz, and N. Prasnikar Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells Pancreatology 2 2002 146 154
19. W.G. Zhu, and G.A. Otterson The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells Curr Med Chem Anticancer Agents 3 2003 187 199
20. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J Clin Oncol 27 2009 5459 5468
21. T. Fujisawa, B.H. Joshi, and R.K. Puri Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer J Transl Med 9 2011 37
22. L.A. Johnson, R.A. Morgan, M.E. Dudley, L. Cassard, J.C. Yang, and M.S. Hughes Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
23. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
24. S.A. Rosenberg, N.P. Restifo, J.C. Yang, R.A. Morgan, and M.E. Dudley Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 2008 299 308
25. Z.Q. Huang, and D.J. Buchsbaum Monoclonal antibodies in the treatment of pancreatic cancer Immunotherapy 1 2009 223 229
26. E. Lutz, C.J. Yeo, K.D. Lillemoe, B. Biedrzycki, B. Kobrin, and J. Herman A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation Ann Surg 253 2011 328 335